Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171190 | 0.91 | ACE (0.57) | TACR1CTSLNQO2CTSSCTSK | |
| SCHEMBL4107361 | 0.87 | NQO2 (0.53) | TACR1CTSLNQO2CTSSCTSK | |
| SCHEMBL7867838 | 0.85 | NQO2 (0.53) | NQO2 | |
| SCHEMBL21310053 | 0.85 | TACR1 (0.62) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL5123229 | 0.85 | TACR1 (0.62) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL14032553 | 0.85 | TACR1 (0.64) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL5123222 | 0.85 | TACR1 (0.62) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL17961907 | 0.84 | TACR1 (0.59) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL31725820 | 0.84 | TACR1 (0.61) | TACR1CTSLNQO2CTSSCTSK | |
| SCHEMBL31277956 | 0.84 | TACR1 (0.61) | TACR1CTSLCTSSCTSKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| EP-1912706-A4 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIE (IN) | 2009-05-27 | — | — | EP | disclosed |
| EP-1912706-A2 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006134613-A2 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | DPP4, DPP3, DPP7 | TACR1 528/4885CTSL 394/4885NQO2 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.